Evidence map›Paper›PMID 37142749›Full record

ArticleNature plants2023

Armadillo repeat-containing kinesin represents the versatile plus-end-directed transporter in Physcomitrella.

Mari W Yoshida, Maya Hakozaki, Gohta Goshima

Abstract read
PubMed Publisher
In one paragraph

Article in Nature plants, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. HomozygousTranslational andrology and urology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. TheInternational journal of molecular sciences · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mari W YoshidaDepartment of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID 0000-0002-4010-3544
Maya HakozakiDepartment of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Gohta GoshimaDepartment of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan. goshima@bio.nagoya-u.ac.jp.ORCID 0000-0001-7524-8770
Nagoya University · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 17H06471MEXT | Japan Society for the Promotion of Science (JSPS) 18KK0202MEXT | Japan Society for the Promotion of Science (JSPS) 22H02644
6 · The paper itself

Abstract

Kinesin-1, also known as conventional kinesin, is widely used for microtubule plus-end-directed (anterograde) transport of various cargos in animal cells. However, a motor functionally equivalent to the conventional kinesin has not been identified in plants, which lack the kinesin-1 genes. Here we show that plant-specific armadillo repeat-containing kinesin (ARK) is the long sought-after versatile anterograde transporter in plants. In ARK mutants of the moss Physcomitrium patens, the anterograde motility of nuclei, chloroplasts, mitochondria and secretory vesicles was suppressed. Ectopic expression of non-motile or tail-deleted ARK did not restore organelle distribution. Another prominent macroscopic phenotype of ARK mutants was the suppression of cell tip growth. We showed that this defect was attributed to the mislocalization of actin regulators, including RopGEFs; expression and forced apical localization of RopGEF3 partially rescued the growth phenotype of the ARK mutant. The mutant phenotypes were partially rescued by ARK homologues in Arabidopsis thaliana, suggesting the conservation of ARK functions in plants.

Indexed as

BryopsidaKinesinsArabidopsisProtein DomainsKinesins

Identifiers

PMID37142749
OpenAlexW4368374050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.